Press Releases

News Brief

Samsung Biologics joins strategic investment in Araris to support collaboration in ADC therapies

Samsung Biologics joins strategic investment in Araris to support collaboration in ADC therapies
 

Samsung Life Science Fund, created jointly between Samsung Biologics (KRX: 207940.KS) and Samsung C&T, and managed by Samsung Ventures, makes investment in Araris Biotech AG, a company pioneering a proprietary antibody-drug conjugate (ADC)-linker technology.

The latest investment reflects Samsung Biologics’ commitment to further expand its pipeline and explore new opportunities in biopharmaceuticals, wherein Samsung affiliates will work with Araris to evaluate, manufacture and develop assets using the biotech’s proprietary ADC technology.

“Araris has the potential to develop best-in-class ADC therapies, and we see room for collaboration in the manufacturing and development of new drugs,” said John Rim, President and CEO of Samsung Biologics.

“We’re pleased to receive this support from Samsung, as well as the recognition of the potential of our linker-payload toolbox and conjugation technology in such a quickly growing ADC field,” said Philipp Spycher, Ph.D., chief executive officer and co-founder of Araris Biotech. “We look forward to using these proceeds to further support our efforts in advancing our ADC candidates toward the clinic.”

Samsung Biologics joins strategic investment in Araris to support collaboration in ADC therapies
 

Samsung Life Science Fund, created jointly between Samsung Biologics (KRX: 207940.KS) and Samsung C&T, and managed by Samsung Ventures, makes investment in Araris Biotech AG, a company pioneering a proprietary antibody-drug conjugate (ADC)-linker technology.

The latest investment reflects Samsung Biologics’ commitment to further expand its pipeline and explore new opportunities in biopharmaceuticals, wherein Samsung affiliates will work with Araris to evaluate, manufacture and develop assets using the biotech’s proprietary ADC technology.

“Araris has the potential to develop best-in-class ADC therapies, and we see room for collaboration in the manufacturing and development of new drugs,” said John Rim, President and CEO of Samsung Biologics.

“We’re pleased to receive this support from Samsung, as well as the recognition of the potential of our linker-payload toolbox and conjugation technology in such a quickly growing ADC field,” said Philipp Spycher, Ph.D., chief executive officer and co-founder of Araris Biotech. “We look forward to using these proceeds to further support our efforts in advancing our ADC candidates toward the clinic.”

SITE MAP

close
Close

Your download is ready

Click Download.

Close

Subscribe to Our Newsletter

Please fill in your details, select one or more areas of interest, and click the subscribe button to receive our newsletter.

Subscribe to Our Newsletter
  • Privacy Policy to collect the email address that I have provided until I withdraw my consent. The collected information will only be used for the purpose of mailing service. If you do not wish to consent, you will not be able to receive the newsletter. Samsung Biologics respects the privacy of its subscribers.
Close

Please fill out the form
to view the full content

Please sign up to view the post..
* Required
Privacy Policy required
close

SECURITY REPORT

Your valuable comments contribute to protecting Samsung Biologic’s core technology and management information, as well as reinforcing domestic competency and economic development.

  • This page is created for reporting core technology and management information leakage.
  • The reported contents as well as the identity of the reporter are strictly secured.
THE MANUAL FOR SECURITY NOTIFICATION